33 results on '"Kropf-Sanchen Cornelia"'
Search Results
2. Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition
- Author
-
Acker, Fabian, Klein, Alexandra, Rasokat, Anna, Eisert, Anna, Kron, Anna, Christopoulos, Petros, Stenzinger, Albrecht, Kulhavy, Jonas, Hummel, Horst-Dieter, Waller, Cornelius F., Hummel, Anne, Rittmeyer, Achim, Kropf-Sanchen, Cornelia, Zimmermann, Heiner, Lörsch, Alisa, Kauffmann-Guerrero, Diego, Schütz, Maret, Herster, Franziska, Thielert, Franziska, Demes, Melanie, Althoff, Friederike C., Aguinarte, Lukas, Heinzen, Sophie, Rost, Maximilian, Schulte, Hanna, Stratmann, Jan, Rohde, Gernot, Büttner, Reinhard, Wolf, Jürgen, Sebastian, Martin, and Michels, Sebastian
- Published
- 2024
- Full Text
- View/download PDF
3. Immune checkpoint inhibitors in non-small cell lung cancer – When should we dare to stop treatment?
- Author
-
Bozorgmehr, Farastuk, Müller, Annette, Rawluk, Justyna, Sianidou, Maria, Chung, Inn, and Kropf-Sanchen, Cornelia
- Published
- 2023
- Full Text
- View/download PDF
4. Young Thoracic Oncologist – 1. YTO Skills Camp und Retreat, Herbst 2021: Eine Initiative der Pneumologisch-onkologischen Arbeitsgemeinschaft (POA)
- Author
-
Loges, Sonja, Schäper, Christoph, Schmidt, Bernd, and Kropf-Sanchen, Cornelia
- Published
- 2022
- Full Text
- View/download PDF
5. Erstmalige interdisziplinäre DKK-Programmplanung durch Zusammenschluss onkologischer Nachwuchsgruppen
- Author
-
Mäurer, Matthias A., Huber, Tobias, Sommer, Nils P., Mäurer, Irina, Lazaridis, Lazaros, Bodensohn, Raphael, Ziegler, Sonia, Fleischmann, Daniel F., Käsmann, Lukas, Staudacher, Jonas, Kropf-Sanchen, Cornelia, Scherg, Alexandra, Wikert, Julia, Pietzner, Klaus, Oing, Christoph, Beyer, Georg, Hollenbach, Marcus, Nestler, Tim, Siech, Carolin, Meyer, Robert, Heinrich, Kathrin, and Stahler, Arndt
- Published
- 2022
- Full Text
- View/download PDF
6. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Targeted Therapies
- Author
-
Acker, Fabian, primary, Luan, Jingting, additional, Soltani Germy, Puyan, additional, Kemper, Marcel, additional, Blasi, Miriam, additional, Griesinger, Frank, additional, Tufman, Amanda, additional, Bleckmann, Annalen, additional, Kropf-Sanchen, Cornelia, additional, and Overbeck, Tobias Raphael, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell Engagers.
- Author
-
Kemper, Marcel, Soltani Germy, Puyan, Acker, Fabian, Luan, Jingting, Griesinger, Frank, Tufman, Amanda, Kropf-Sanchen, Cornelia, Overbeck, Tobias Raphael, Bleckmann, Annalen, and Blasi, Miriam
- Subjects
MEDICAL societies ,T cells ,SMALL cell lung cancer ,ONCOLOGY - Abstract
This document summarizes the key findings and insights from the 2023 European Society for Medical Oncology (ESMO) annual meeting, with a focus on thoracic oncology. It covers various topics such as immunotherapy-based therapy in nonmetastatic settings, radiotherapy in non-small cell lung cancer (NSCLC), and bispecific T-cell engagers in small cell lung cancer (SCLC). The report includes data from clinical trials and studies, highlighting the effectiveness and safety of different treatment approaches. It also mentions the approval of certain therapies by regulatory bodies and emphasizes the need for further research in specific patient subgroups. Authored by a team of experts, this report provides valuable insights and perspectives for library patrons conducting research in this field. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. Apnea and heart rate detection from tracheal body sounds for the diagnosis of sleep-related breathing disorders
- Author
-
Kalkbrenner, Christoph, Eichenlaub, Manuel, Rüdiger, Stefan, Kropf-Sanchen, Cornelia, Rottbauer, Wolfgang, and Brucher, Rainer
- Published
- 2018
- Full Text
- View/download PDF
9. Neoadjuvante Therapie des nicht-kleinzelligen Lungenkarzinoms
- Author
-
Gillissen, Adrian, primary and Kropf-Sanchen, Cornelia, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Adjuvante Therapie des nicht-kleinzelligen Lungenkarzinoms
- Author
-
Kropf-Sanchen, Cornelia, primary and Gillissen, Adrian, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
- Author
-
Deininger, Katharina, Raacke, Joel Niclas, Yousefzadeh-Nowshahr, Elham, Kropf-Sanchen, Cornelia, Muehling, Bernd, Beer, Meinrad, Glatting, Gerhard, Beer, Ambros J., and Thaiss, Wolfgang
- Published
- 2023
- Full Text
- View/download PDF
12. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
- Author
-
Kahnert, Kathrin, Andreas, Stefan, Kellerer, Christina, Lutter, Johanna I., Lucke, Tanja, Yildirim, Önder, Lehmann, Mareike, Seissler, Jochen, Behr, Jürgen, Frankenberger, Marion, Bals, Robert, Watz, Henrik, Welte, Tobias, Trudzinski, Franziska C., Vogelmeier, Claus F., Alter, Peter, Jörres, Rudolf A., Bahmer, Thomas, Bewig, Burkhard, Ewert, Ralf, Stubbe, Beate, Ficker, Joachim H., Grohé, Christian, Held, Matthias, Henke, Markus, Herth, Felix, Kirsten, Anne-Marie, Koczulla, Rembert, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Herzmann, Christian, Pfeifer, Michael, Randerath, Winfried J., Seeger, Werner, Studnicka, Michael, Taube, Christian, Timmermann, Hartmut, Schmeck, Bernd, Vogelmeier, Claus, and Wirtz, Hubert
- Subjects
Male ,Epidemiology ,Science ,Vital Capacity ,Medizin ,Article ,Body Mass Index ,Cohort Studies ,Pulmonary Disease, Chronic Obstructive ,Sex Factors ,Forced Expiratory Volume ,Diabetes Mellitus ,Humans ,Hypoglycemic Agents ,Lung ,Aged ,Multidisciplinary ,Smoking ,Age Factors ,Middle Aged ,respiratory system ,Metformin ,respiratory tract diseases ,Pulmonary Emphysema ,Pulmonary Diffusing Capacity ,Medicine ,Female ,Drug therapy - Abstract
We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1–4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV1, FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively; p 1 and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema.
- Published
- 2022
13. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
- Author
-
von Siemens, Sarah Marietta, Perneczky, Robert, Waschki, Benjamin, Lutter, Johanna I, Welte, Tobias, Jörres, Rudolf A, Kahnert, Kathrin, group, COSYCONET study, Andreas, Stefan, Bals, Robert, Behr, Jürgen, Vogelmeier, Claus F, Bewig, Burkhard, Buhl, Roland, Ewert, Ralf, Stubbe, Beate, Gogol, Manfred, Grohé, Christian, Hauck, Rainer, Held, Matthias, Jany, Berthold, Henke, Markus, Herth, Felix, Höffken, Gerd, Katus, Hugo A, Kirsten, Anne-Marie, Watz, Henrik, Koczulla, Rembert, Kenn, Klaus, Kronsbein, Juliane, Kropf-Sanchen, Cornelia, Lange, Christoph, Kauffmann-Guerrero, Diego, Zabel, Peter, Pfeifer, Michael, Randerath, Winfried J, Seeger, Werner, Studnicka, Michael, Taube, Christian, Teschler, Helmut, Timmermann, Hartmut, Virchow, J Christian, Vogelmeier, Claus, Alter, Peter, Wagner, Ulrich, Wirtz, Hubert, Trudzinski, Franziska C, and Söhler, Sandra
- Subjects
Male ,medicine.medical_specialty ,epidemiology [Cognitive Dysfunction] ,psychology [Pulmonary Disease, Chronic Obstructive] ,Medizin ,Comorbidity ,Cohort Studies ,03 medical and health sciences ,FEV1/FVC ratio ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Cognition ,epidemiology [Pulmonary Disease, Chronic Obstructive] ,Surveys and Questionnaires ,medicine ,Dementia ,Humans ,COPD ,Cognitive Dysfunction ,ddc:610 ,Cognitive skill ,Path analysis (statistics) ,Aged ,lcsh:RC705-779 ,business.industry ,Research ,physiology [Cognition] ,diagnosis [Pulmonary Disease, Chronic Obstructive] ,lcsh:Diseases of the respiratory system ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,humanities ,Cross-Sectional Studies ,Cognitive impairment ,diagnosis [Cognitive Dysfunction] ,030228 respiratory system ,Cohort ,Physical therapy ,Female ,psychology [Cognitive Dysfunction] ,business ,030217 neurology & neurosurgery ,Cognitive load - Abstract
Alterations of cognitive functions have been described in COPD. Our study aimed to disentangle the relationship between the degree of cognitive function and COPD characteristics including quality of life (QoL).Data from 1969 COPD patients of the COSYCONET cohort (GOLD grades 1–4; 1216 male/ 753 female; mean (SD) age 64.9 ± 8.4 years) were analysed using regression and path analysis. The DemTect screening tool was used to measure cognitive function, and the St. George‘s respiratory questionnaire (SGRQ) to assess disease-specific QoL.DemTect scores were =60 years of age. For statistical reasons, we used the average of both algorithms independent of age in all subsequent analyses. The DemTect scores were associated with oxygen content, 6-min-walking distance (6-MWD), C-reactive protein (CRP), modified Medical Research Council dyspnoea scale (mMRC) and the SGRQ impact score. Conversely, the SGRQ impact score was independently associated with 6-MWD, FVC, mMRC and DemTect. These results were combined into a path analysis model to account for direct and indirect effects. The DemTect score had a small, but independent impact on QoL, irrespective of the inclusion of COPD-specific influencing factors or a diagnosis of cognitive impairment.We conclude that in patients with stable COPD lower oxygen content of blood as a measure of peripheral oxygen supply, lower exercise capacity in terms of 6-MWD, and higher CRP levels were associated with reduced cognitive capacity. Furthermore, a reduction in cognitive capacity was associated with reduced disease-specific quality of life. As a potential clinical implication of this work, we suggest to screen especially patients with low oxygen content and low 6-MWD for cognitive impairment.
- Published
- 2022
- Full Text
- View/download PDF
14. Long COVID: Distinction between Organ Damage and Deconditioning
- Author
-
Kersten, Johannes, primary, Baumhardt, Michael, additional, Hartveg, Paul, additional, Hoyo, Luis, additional, Hüll, Elina, additional, Imhof, Armin, additional, Kropf-Sanchen, Cornelia, additional, Nita, Nicoleta, additional, Mörike, Johannes, additional, Rattka, Manuel, additional, Andreß, Stefanie, additional, Scharnbeck, Dominik, additional, Schmidtke-Schrezenmeier, Gerlinde, additional, Tadic, Marijana, additional, Wolf, Alexander, additional, Rottbauer, Wolfgang, additional, and Buckert, Dominik, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Impact of continuous, non-invasive blood pressure measurement on sleep quality during polysomnography
- Author
-
Wibmer, Thomas, Schildge, Benedikt, Fischer, Christoph, Brunner, Stefanie, Kropf-Sanchen, Cornelia, Rüdiger, Stefan, Blanta, Ioanna, Stoiber, Kathrin M., Rottbauer, Wolfgang, and Schumann, Christian
- Published
- 2013
- Full Text
- View/download PDF
16. Histology as a Potential Clinical Predictor of Outcome in Advanced Non-Small-Cell Lung Cancer Treated with Vinorelbine and Mitomycin Combination Chemotherapy
- Author
-
Wibmer, Thomas, Berghmans, Thierry, Kropf-Sanchen, Cornelia, Lafitte, Jean-Jacques, Rüdiger, Stefan, Paesmans, Marianne, Blanta, Ioanna, Scherpereel, Arnaud, Stoiber, Kathrin M., Rottbauer, Wolfgang, Sculier, Jean-Paul, and Schumann, Christian
- Published
- 2013
- Full Text
- View/download PDF
17. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET
- Author
-
Kirsten Anne-Marie, Anne Wirz, Erich Traugott, Ficker Joachim H, Bertram J. Jobst, Vivien Janke, Stubbe Beate, Johanna I. Lutter, Barbara Ziss, Franziska C. Trudzinski, Patricia Berger, Henrik Watz, Gogol Manfred, Thomas Bahmer, Beate Polte, Kronsbein Juliane, Campus Kiel, Lange Christoph, Martina Seibert, Rudolf A. Jörres, Pfeifer Michael, Timmermann Hartmut, Grohé Christian, Tobias Welte, Studnicka Michael, Petra Hundack-Winter, Jana Graf, Jürgen Behr, Diana Schottel, Buhl Roland, Virchow J. Christian, Bewig Burkhard, Ruhrlandklinik gGmbH. Essen, Wirtz Hubert, Rosalie Untsch, Birte Struck, Peter Alter, Kathrin Kahnert, Gudrun Hübner, Vogelmeier Claus, Sabine Michalewski, Kropf-Sanchen Cornelia, Kenn Klaus, Pontus Mertsch, Sonja Rohweder, Hauck Rainer, Andreas Stefan, Ilona Kietzmann, Zabel Peter, Michaela Schrade-Illmann, Höffken Gerd, Julia Tobias, Frank Biertz, Seeger Werner, Manuel Klöser, Kahnert Kathrin, Teschler Helmut, Anita Reichel, Gina Spangel, Ulrike Rieber, Randerath Winfried J, Julia Teng, Tanja Lucke, Herth Felix, Jeanette Pieper, Lenka Krabbe, Taube Christian, Jürgen Biederer, Wagner Ulrich, Doris Lehnert, Claus Vogelmeier, Katrin Schwedler, Henke Markus, Jany Berthold, Katus Hugo A, Bals Robert, Zaklina Hinz, Cornelia Böckmann, Ellen Burmann, Margret Gleiniger, Behr Jürgen, Britta Markworth, Ewert Ralf, Gertraud Weiß, Katrin Wons, Barbara Arikan, Watz Henrik, Beate Schaufler, Lena Sterk, Robert Bals, Hans-Ulrich Kauczor, Koczulla Rembert, Held Matthias, and Welte Tobias
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Copd patients ,Medizin ,Comorbidity ,Severity of Illness Index ,Pulmonary Disease, Chronic Obstructive ,Medicine ,Humans ,In patient ,Lung ,Aged ,Aged, 80 and over ,COPD ,Bronchiectasis ,business.industry ,Phlegm ,Middle Aged ,medicine.disease ,Radiological weapon ,Clinical diagnosis ,Cohort ,Female ,Radiography, Thoracic ,Radiology ,medicine.symptom ,business ,Tomography, X-Ray Computed - Abstract
Bronchiectasis (BE) might be frequently present in COPD but masked by COPD symptoms. We studied the relationship of clinical signs of bronchiectasis to the presence and extent of its radiological signs in patients of different COPD severity. Visit 4 data (GOLD grades 1-4) of the COSYCONET cohort was used. Chest CT scans were evaluated for bronchiectasis in 6 lobes using a 3-point scale (0: absence, 1: ≤50%, 2: >50% BE-involvement for each lobe). 1176 patients were included (61%male, age 67.3y), among them 38 (3.2%) with reported physicians' diagnosis of bronchiectasis and 76 (6.5%) with alpha1-antitrypsin deficiency (AA1D). CT scans were obtained in 429 patients. Within this group, any signs of bronchiectasis were found in 46.6% of patients, whereby ≤50% BE occurred in 18.6% in ≤2 lobes, in 10.0% in 3-4 lobes, in 15.9% in 5-6 lobes; >50% bronchiectasis in at least 1 lobe was observed in 2.1%. Scores ≥4 correlated with an elevated ratio FRC/RV. The clinical diagnosis of bronchiectasis correlated with phlegm and cough and with radiological scores of at least 3, optimally ≥5. In COPD patients, clinical diagnosis and radiological signs of BE showed only weak correlations. Correlations became significant with increasing BE-severity implying radiological alterations in several lobes. This indicates the importance of reporting both presence and extent of bronchiectasis on CT. Further research is warranted to refine the criteria for CT scoring of bronchiectasis and to determine the relevance of radiologically but not clinically detectible bronchiectasis and their possible implications for therapy in COPD patients.
- Published
- 2020
18. CAT score single item analysis in patients with COPD: results from COSYCONET
- Author
-
J. Randerath Winfried, Pfeifer Michael, Kenn Klaus, Joachim H. Ficker, Gogol Manfred, Grohé Christian, Höffken Gerd, Zaklina Hinz, Julia Tobias, Henke Markus, Teschler Helmut, Welte Tobias, Benjamin Waschki, Buhl Roland, Paul W. Jones, Kirsten Anne-Marie, A. Katus Hugo, Taube Christian, Bewig Burkhard, Beate Polte, Kronsbein Juliane, Stubbe Beate, Bals Robert, Johanna I. Lutter, Sarah Marietta von Siemens, Lange Christoph, Vogelmeier Claus, Ellen Burmann, Wirtz Hubert, Kathrin Kahnert, Erich Traugott, Behr Jürgen, Birte Struck, Vivien Janke, Lenka Krabbe, Timmermann Hartmut, Wagner Ulrich, Anita Reichel, Sabine Michalewski, Gudrun Hübner, Seeger Werner, Doris Lehnert, Jany Berthold, Kropf-Sanchen Cornelia, Sandra Söhler, Jeanette Pieper, Ulrike Rieber, Peter Alter, Herth Felix, Zabel Peter, Andreas Stefan, Koczulla Rembert, Held Matthias, Tobias Welte, Franziska C. Trudzinski, Patricia Berger, Kahnert Kathrin, Jana Graf, Jürgen Behr, Rosalie Untsch, Rudolf A. Jörres, Kornelia Speth, Britta Markworth, Ewert Ralf, Gertraud Weiß, Hans-Ulrich Kauczor, Claus Vogelmeier, Katrin Schwedler, Katrin Wons, Bertram J. Jobst, Barbara Arikan, Margret Gleiniger, Henrik Watz, Watz Henrik, Studnicka Michael, Beate Schaufler, Diana Schottel, Sonja Rohweder, Robert Bals, Ilona Kietzmann, Virchow J. Christian, Burkhard Bewig, Hauck Rainer, and Michaela Schrade-Illmann
- Subjects
Pulmonary and Respiratory Medicine ,Percentile ,medicine.medical_specialty ,Medizin ,Diagnostic Techniques, Respiratory System ,Single item ,CAT score ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Internal medicine ,medicine ,COPD ,In patient ,030212 general & internal medicine ,Lung function ,Emphysema ,business.industry ,Regression analysis ,Cat Score ,Copd ,medicine.disease ,Exploratory factor analysis ,respiratory tract diseases ,030228 respiratory system ,Cohort ,business - Abstract
The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items against a panel of comorbidities, lung function, or CT characteristics (qualitative score, 15th percentile of mean lung density), with age, BMI and gender as covariates. This was supported by exploratory factor analysis. Regarding the relationship to comorbidities and emphysema, there were marked differences between CAT items, especially items 1 and 2 versus 3 to 8. This grouping was basically confirmed by factor analysis. Items 4 and 5, and to a lower degree 1, 2 and 6, appeared to be informative regarding the presence of emphysema, whereas the total score was not or less informative. Regarding comorbidities, similar findings as for the total CAT score were obtained for the modified Medical Research Council scale (mMRC) which was also informative regarding emphysema. Our findings suggest that the usefulness of the CAT can be increased if evaluated on the basis of single items which may be indicating the presence of comorbidities and emphysema.
- Published
- 2020
19. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
- Author
-
Kaemmerer, Harald, Gorenflo, Matthias, Huscher, Dorte, Pittrow, David, Apitz, Christian, Baumgartner, Helmut, Berger, Felix, Bruch, Leonhard, Brunnemer, Eva, Budts, Werner, Claussen, Martin, Coghlan, Gerry, Dahnert, Ingo, D'Alto, Michele, Delcroix, Marion, Distler, Oliver, Dittrich, Sven, Dumitrescu, Daniel, Ewert, Ralf, Faehling, Martin, Germund, Ingo, Ghofrani, Hossein Ardeschir, Grohe, Christian, Grossekreymborg, Karsten, Halank, Michael, Hansmann, Georg, Harzheim, Dominik, Nemes, Attila, Havasi, Kalman, Held, Matthias, Hoeper, Marius M., Hofbeck, Michael, Hohenfrost-Schmidt, Wolfgang, Jureviciene, Elena, Gumbiene, Lina, Kabitz, Hans-Joachim, Klose, Hans, Koehler, Thomas, Konstantinides, Stavros, Koeestenberger, Martin, Kozlik-Feldmann, Rainer, Kramer, Hans-Heiner, Kropf-Sanchen, Cornelia, Lammers, Astrid, Lange, Tobias, Meyn, Philipp, Miera, Oliver, Milger-Kneidinger, Katrin, Neidenbach, Rhoia, Neurohr, Claus, Opitz, Christian, Perings, Christian, Remppis, Bjoern Andrew, Riemekasten, Gabriele, Scelsi, Laura, Scholtz, Werner, Simkova, Iveta, Skowasch, Dirk, Skride, Andris, Staehler, Gerd, Stiller, Brigitte, Tsangaris, Iraklis, Vizza, Carmine Dario, Noordegraaf, Anton Vonk, Wilkens, Heinrike, Wirtz, Hubert, Diller, Gerhard-Paul, Gruenig, Ekkehard, Rosenkranz, Stephan, Kaemmerer, Harald, Gorenflo, Matthias, Huscher, Dorte, Pittrow, David, Apitz, Christian, Baumgartner, Helmut, Berger, Felix, Bruch, Leonhard, Brunnemer, Eva, Budts, Werner, Claussen, Martin, Coghlan, Gerry, Dahnert, Ingo, D'Alto, Michele, Delcroix, Marion, Distler, Oliver, Dittrich, Sven, Dumitrescu, Daniel, Ewert, Ralf, Faehling, Martin, Germund, Ingo, Ghofrani, Hossein Ardeschir, Grohe, Christian, Grossekreymborg, Karsten, Halank, Michael, Hansmann, Georg, Harzheim, Dominik, Nemes, Attila, Havasi, Kalman, Held, Matthias, Hoeper, Marius M., Hofbeck, Michael, Hohenfrost-Schmidt, Wolfgang, Jureviciene, Elena, Gumbiene, Lina, Kabitz, Hans-Joachim, Klose, Hans, Koehler, Thomas, Konstantinides, Stavros, Koeestenberger, Martin, Kozlik-Feldmann, Rainer, Kramer, Hans-Heiner, Kropf-Sanchen, Cornelia, Lammers, Astrid, Lange, Tobias, Meyn, Philipp, Miera, Oliver, Milger-Kneidinger, Katrin, Neidenbach, Rhoia, Neurohr, Claus, Opitz, Christian, Perings, Christian, Remppis, Bjoern Andrew, Riemekasten, Gabriele, Scelsi, Laura, Scholtz, Werner, Simkova, Iveta, Skowasch, Dirk, Skride, Andris, Staehler, Gerd, Stiller, Brigitte, Tsangaris, Iraklis, Vizza, Carmine Dario, Noordegraaf, Anton Vonk, Wilkens, Heinrike, Wirtz, Hubert, Diller, Gerhard-Paul, Gruenig, Ekkehard, and Rosenkranz, Stephan
- Abstract
Introduction: Pulmonary hypertension (PH) is a common complication in patients with congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and clinical outcomes among each other and compared with other diseases with pulmonary hypertension. Objective: To describe current management strategies and outcomes for adults with PH in relation to different types of CHD based on real-world data. Methods and results: COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective, international PH registry comprising, at the time of data analysis, >8200 patients with various forms of PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between 2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At enrollment, the patients' median age was 44 years (67% female), and patients had either pre-tricuspid shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH) included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naive. While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients), with 30% of the patients on combination therapy, after a median observation time of 45.3 months, the number of patients on combination therapy had increased significantly, to 50%. The use of oral anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91 patients died over the course of a 5-year follow up. Th
- Published
- 2020
20. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
- Author
-
Kaemmerer, Harald, primary, Gorenflo, Matthias, additional, Huscher, Dörte, additional, Pittrow, David, additional, Apitz, Christian, additional, Baumgartner, Helmut, additional, Berger, Felix, additional, Bruch, Leonhard, additional, Brunnemer, Eva, additional, Budts, Werner, additional, Claussen, Martin, additional, Coghlan, Gerry, additional, Dähnert, Ingo, additional, D’Alto, Michele, additional, Delcroix, Marion, additional, Distler, Oliver, additional, Dittrich, Sven, additional, Dumitrescu, Daniel, additional, Ewert, Ralf, additional, Faehling, Martin, additional, Germund, Ingo, additional, Ghofrani, Hossein Ardeschir, additional, Grohé, Christian, additional, Grossekreymborg, Karsten, additional, Halank, Michael, additional, Hansmann, Georg, additional, Harzheim, Dominik, additional, Nemes, Attila, additional, Havasi, Kalman, additional, Held, Matthias, additional, M. Hoeper, Marius, additional, Hofbeck, Michael, additional, Hohenfrost-Schmidt, Wolfgang, additional, Jurevičienė, Elena, additional, Gumbienè, Lina, additional, Kabitz, Hans-Joachim, additional, Klose, Hans, additional, Köhler, Thomas, additional, Konstantinides, Stavros, additional, Köestenberger, Martin, additional, Kozlik-Feldmann, Rainer, additional, Kramer, Hans-Heiner, additional, Kropf-Sanchen, Cornelia, additional, Lammers, Astrid, additional, Lange, Tobias, additional, Meyn, Philipp, additional, Miera, Oliver, additional, Milger-Kneidinger, Katrin, additional, Neidenbach, Rhoia, additional, Neurohr, Claus, additional, Opitz, Christian, additional, Perings, Christian, additional, Remppis, Bjoern Andrew, additional, Riemekasten, Gabriele, additional, Scelsi, Laura, additional, Scholtz, Werner, additional, Simkova, Iveta, additional, Skowasch, Dirk, additional, Skride, Andris, additional, Stähler, Gerd, additional, Stiller, Brigitte, additional, Tsangaris, Iraklis, additional, Vizza, Carmine Dario, additional, Vonk Noordegraaf, Anton, additional, Wilkens, Heinrike, additional, Wirtz, Hubert, additional, Diller, Gerhard-Paul, additional, Grünig, Ekkehard, additional, and Rosenkranz, Stephan, additional
- Published
- 2020
- Full Text
- View/download PDF
21. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort
- Author
-
F.C. Trudzinski, K. Kahnert, C.F. Vogelmeier, P. Alter, F. Seiler, S. Fähndrich, H. Watz, T. Welte, T. Speer, S. Zewinger, F. Biertz, H.-U. Kauczor, R.A. Jörres, R. Bals, Andreas Stefan, Bals Robert, Behr Jürgen, Kahnert Kathrin, Bewig Burkhard, Buhl Roland, Ewert Ralf, Stubbe Beate, Ficker Joachim H, Gogol Manfred, Grohé Christian, Hauck Rainer, Held Matthias, Jany Berthold, Henke Markus, Herth Felix, Höffken Gerd, Katus Hugo A, Kirsten Anne-Marie, Watz Henrik, Koczulla Rembert, Kenn Klaus, Kronsbein Juliane, Kropf-Sanchen Cornelia, Lange Christoph, Zabel Peter, Pfeifer Michael, Randerath Winfried J, null eeger Werner, Studnicka Michael, Taube Christian, Teschler Helmut, Timmermann Hartmut, Virchow J. Christian, Vogelmeier Claus, Wagner Ulrich, Welte Tobias, and Wirtz Hubert
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Exacerbation ,Partial Pressure ,Medizin ,Renal function ,Comorbidity ,Acid-Base Imbalance ,Kidney Function Tests ,Risk Assessment ,Cohort Studies ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,DLCO ,Diffusing capacity ,Internal medicine ,Forced Expiratory Volume ,medicine ,Humans ,Respiratory function ,030212 general & internal medicine ,Aged ,COPD ,Carbon Monoxide ,business.industry ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Respiratory Function Tests ,Cross-Sectional Studies ,030228 respiratory system ,Cohort ,Cardiology ,Disease Progression ,Pulmonary Diffusing Capacity ,Female ,Blood Gas Analysis ,Risk assessment ,business ,Glomerular Filtration Rate - Abstract
Rationale Alterations of acid-base metabolism are an important outcome predictor in acute exacerbations of COPD, whereas sufficient metabolic compensation and adequate renal function are associated with decreased mortality. In stable COPD there is, however, only limited information on the combined role of acid-base balance, blood gases, renal and respiratory function on exacerbation risk grading. Methods We used baseline data of the COPD cohort COSYCONET, applying linear and logistic regression analyses, the results of which were implemented into a comprehensive structural equation model. As most informative parameters it comprised the estimated glomerular filtration rate (eGFR), lung function defined via forced expiratory volume in 1 s (FEV1), intrathoracic gas volume (ITGV) and (diffusing capacity for carbon monoxide (DLCO), moreover arterial oxygen content (CaO2), partial pressure of oxygen (PaCO2), base exess (BE) and exacerbation risk according to GOLD criteria. All measures were adjusted for age, gender, body-mass index, the current smoking status and pack years. Results 1506 patients with stable COPD (GOLD grade 1–4; mean age 64.5 ± 8.1 y; mean FEV1 54 ± 18 %predicted, mean eGFR 82.3 ± 16.9 mL/min/1.73 m2) were included. BE was linked to eGFR, lung function and PaCO2 and played a role as indirect predictor of exacerbation risk via these measures; moreover, eGFR was directly linked to exacerbation risk. These associations remained significant after taking into account medication (diuretics, oral and inhaled corticosteroids), whereby corticosteroids had effects on exacerbation risk and lung function, diuretics on eGFR, BE and lung function. Conclusion Even in stable COPD acid-base metabolism plays a key integrative role in COPD risk assessment despite rather small deviations from normality. It partially mediates the effects of impairments in kidney function, which are also directly linked to exacerbation risk.
- Published
- 2019
22. Validation of a New System Using Tracheal Body Sound and Movement Data for Automated Apnea-Hypopnea Index Estimation
- Author
-
Kalkbrenner, Christoph, primary, Eichenlaub, Manuel, additional, Rüdiger, Stefan, additional, Kropf-Sanchen, Cornelia, additional, Brucher, Rainer, additional, and Rottbauer, Wolfgang, additional
- Published
- 2017
- Full Text
- View/download PDF
23. Apnea and heart rate detection from tracheal body sounds for the diagnosis of sleep-related breathing disorders
- Author
-
Kalkbrenner, Christoph, primary, Eichenlaub, Manuel, additional, Rüdiger, Stefan, additional, Kropf-Sanchen, Cornelia, additional, Rottbauer, Wolfgang, additional, and Brucher, Rainer, additional
- Published
- 2017
- Full Text
- View/download PDF
24. P1.07-003 A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC
- Author
-
Grohé, Christian, primary, Engel-Riedel, Walburga, additional, Kropf-Sanchen, Cornelia, additional, Joachim, Von Pawel, additional, Gütz, Sylvia, additional, Kollmeier, Jens, additional, Eberhardt, Wilfried, additional, Christopoulos, Petros, additional, Nimmrich, Inko, additional, Sieder, Christian, additional, Baum, Volker, additional, Serke, Monika, additional, and Thomas, Michael, additional
- Published
- 2017
- Full Text
- View/download PDF
25. Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
- Author
-
Rudiger, Stefan, primary, Kropf-Sanchen, Cornelia, additional, Schmidtke-Schrezenmeier, Gerlinde, additional, Aksentiy, Marta, additional, Hoss, Katja, additional, and Rottbauer, Wolfgang, additional
- Published
- 2016
- Full Text
- View/download PDF
26. Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)
- Author
-
Reck, Martin, primary, Thomas, Michael, additional, Kropf-Sanchen, Cornelia, additional, Mezger, Jörg, additional, Socinski, Mark A., additional, Depenbrock, Henrik, additional, Soldatenkova, Victoria, additional, Brown, Jacqueline, additional, Krause, Thomas, additional, and Thatcher, Nick, additional
- Published
- 2016
- Full Text
- View/download PDF
27. ROS1 rearrangements in lung adenocarcinoma : prognostic impact, therapeutic options and genetic variability
- Author
-
Scheffler, Matthias, Schultheis, Anne Maria, Teixido, Cristina, Michels, Sebastian Yves Friedrich, Morales-Espinosa, Daniela, Viteri, Santiago, Hartmann, Wolfgang, Merkelbach-Bruse, Sabine, Fischer, Rieke, Schildhaus, Hans-Ulrich, Fassunke, Jana, Sebastian, Martin, Serke, Monika Heidi, Kaminsky, Britta, Randerath, Winfried J., Gerigk, Ulrich, Ko, Yon-Dschun, Krüger, Stefan, Schnell, Roland, Rothe, Achim, Kropf-Sanchen, Cornelia, Heukamp, Lukas C., Rosell, Rafael, Büttner, Reinhard, Wolf, Jürgen, Scheffler, Matthias, Schultheis, Anne Maria, Teixido, Cristina, Michels, Sebastian Yves Friedrich, Morales-Espinosa, Daniela, Viteri, Santiago, Hartmann, Wolfgang, Merkelbach-Bruse, Sabine, Fischer, Rieke, Schildhaus, Hans-Ulrich, Fassunke, Jana, Sebastian, Martin, Serke, Monika Heidi, Kaminsky, Britta, Randerath, Winfried J., Gerigk, Ulrich, Ko, Yon-Dschun, Krüger, Stefan, Schnell, Roland, Rothe, Achim, Kropf-Sanchen, Cornelia, Heukamp, Lukas C., Rosell, Rafael, Büttner, Reinhard, and Wolf, Jürgen
- Abstract
Background: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1- positive patients. Patients and methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations. Conclusion: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
- Published
- 2015
28. Blood pressure monitoring during exercise: Comparison of pulse transit time and volume clamp methods
- Author
-
Wibmer, Thomas, primary, Denner, Coy, additional, Fischer, Christoph, additional, Schildge, Benedikt, additional, Rüdiger, Stefan, additional, Kropf-Sanchen, Cornelia, additional, Rottbauer, Wolfgang, additional, and Schumann, Christian, additional
- Published
- 2015
- Full Text
- View/download PDF
29. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
- Author
-
Scheffler, Matthias, primary, Schultheis, Anne, additional, Teixido, Cristina, additional, Michels, Sebastian, additional, Morales-Espinosa, Daniela, additional, Viteri, Santiago, additional, Hartmann, Wolfgang, additional, Merkelbach-Bruse, Sabine, additional, Fischer, Rieke, additional, Schildhaus, Hans-Ulrich, additional, Fassunke, Jana, additional, Sebastian, Martin, additional, Serke, Monika, additional, Kaminsky, Britta, additional, Randerath, Winfried, additional, Gerigk, Ulrich, additional, Ko, Yon-Dschun, additional, Krüger, Stefan, additional, Schnell, Roland, additional, Rothe, Achim, additional, Kropf-Sanchen, Cornelia, additional, Heukamp, Lukas, additional, Rosell, Rafael, additional, Büttner, Reinhard, additional, and Wolf, Jürgen, additional
- Published
- 2015
- Full Text
- View/download PDF
30. Relation of Exercise Capacity With Lung Volumes Before and After 6-Minute Walk Test in Subjects With COPD
- Author
-
Wibmer, Thomas, primary, Rüdiger, Stefan, additional, Kropf-Sanchen, Cornelia, additional, Stoiber, Kathrin M, additional, Rottbauer, Wolfgang, additional, and Schumann, Christian, additional
- Published
- 2014
- Full Text
- View/download PDF
31. Isolated IgG4-related interstitial lung disease: unusual histological and radiological features of a pathologically proven case
- Author
-
Wibmer, Thomas, primary, Kropf-Sanchen, Cornelia, additional, Rüdiger, Stefan, additional, Blanta, Ioanna, additional, Stoiber, Kathrin M., additional, Rottbauer, Wolfgang, additional, and Schumann, Christian, additional
- Published
- 2013
- Full Text
- View/download PDF
32. Effects of Nasal Positive Expiratory Pressure on Dynamic Hyperinflation and 6-Minute Walk Test in Patients With COPD.
- Author
-
Wibmer, Thomas, Rüdiger, Stefan, Heitner, Claudia, Kropf-Sanchen, Cornelia, Blanta, Ioanna, Stoiber, Kathrin M, Rottbauer, Wolfgang, and Schumann, Christian
- Subjects
ARTIFICIAL respiration ,OBSTRUCTIVE lung diseases ,PLETHYSMOGRAPHY ,SPIROMETRY ,STATISTICAL hypothesis testing ,T-test (Statistics) ,POSITIVE pressure ventilation ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
INTRODUCTION: Dynamic hyperinflation is an important target in the treatment of COPD. There is increasing evidence that positive expiratory pressure (PEP) could reduce dynamic hyperinflation during exercise. PEP application through a nasal mask and a flow resistance device might have the potential to be used during daily physical activities as an auxiliary strategy of ventilatory assistance. The aim of this study was to determine the effects of nasal PEP on lung volumes during physical exercise in patients with COPD. METHODS: Twenty subjects (mean ± SD age 69.4 ± 6.4 years) with stable mild-to-severe COPD were randomized to undergo physical exercise with nasal PEP breathing, followed by physical exercise with habitual breathing, or vice versa. Physical exercise was induced by a standard 6-min walk test (6MWT) protocol. PEP was applied by means of a silicone nasal mask loaded with a fixed-orifice flow resistor. Body plethysmography was performed immediately pre-exercise and post-exercise. RESULTS: Differences in mean pre- to post-exercise changes in total lung capacity (_0.63 ± 0.80 L, P = .002), functional residual capacity (-0.48 ± 0.86 L, P = .021), residual volume (-0.56± 0.75 L, P = .004), SpO2 (-1.7 ± 3.4%, P = .041), and 6MWT distance (-30.8 ± 30.0 m, P = .001) were ±tatistically significant between the experimental and the control interventions. CONCLUSIONS: The use of flow-dependent expiratory pressure, applied with a nasal mask and a PEP device, might promote significant reduction of dynamic hyperinflation during walking exercise. Further studies are warranted addressing improvements in endurance performance under regular application of nasal PEP during physical activities. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
- Author
-
Deininger K, Raacke JN, Yousefzadeh-Nowshahr E, Kropf-Sanchen C, Muehling B, Beer M, Glatting G, Beer AJ, and Thaiss W
- Subjects
- Humans, Female, Aged, Prognosis, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18 therapeutic use, Prospective Studies, Biomarkers, Retrospective Studies, Tumor Burden, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology
- Abstract
Aim: The aim of this study was to derive prognostic parameters from 2-[
18 F]fluoro-2-deoxy-D-glucose ([18 F]FDG-PET/CT) in patients with low-risk NSCLC and determine their prognostic value., Methods: 81 (21 female, mean age 66 a) therapy-naive patients that underwent [18F]FDG-PET/CT before histologic confirmation of NSCLC with stadium I and II between 2008-2016 were included. A mean follow-up time of 58 months (13-176), overall and progression free survival (OS, PFS) were registered. A volume of interest for the primary tumor was defined on PET and CT images. Parameters SUVmax , PET-solidity, PET-circularity, and CT-volume were analyzed. To evaluate the prognostic value of each parameter for OS, a minimum p-value approach was used to define cutoff values, survival analysis, and log-rank tests were performed, including subgroup analysis for combinations of parameters., Results: Mean OS was 58±28 months. Poor OS was associated with a tumor CT-volume >14.3 cm3 (p=0.02, HR=7.0, CI 2.7-17.7), higher SUVmax values >12.2 (p=0.003; HR=3.0, CI 1.3-6.7) and PET-solidity >0.919 (p=0.004; HR=3.0, CI 1.0-8.9). Combined parameter analysis revealed worse prognosis in larger volume/high SUVmax tumors compared to larger volume/lower SUVmax (p=0.028; HR=2.5, CI 1.1-5.5), high PET-solidity/low volume (p=0.01; HR=2.4, CI 0.8-6.6) and low SUVmax /high PET-solidity (p=0.02, HR=4.0, CI 0.8-19.0)., Conclusion: Even in this group of low-risk NSCLC patients, we identified a subgroup with a significantly worse prognosis by combining morphologic-metabolic biomarkers from [18F]FDG-PET/CT. The combination of SUVmax and CT-volume performed best. Based on these preliminary data, future prospective studies to validate this combined morphologic-metabolic imaging biomarker for potential therapeutic decisions seem promising., Competing Interests: Beer AJ: AAA GmbH - Honorar Vortragstätigkeit Advisory Board Meeting Janssen-Cilag - Honorar Vortragstätigkeit VSRN Baden-Baden über KelCon - Honorar Vortragstätigkeit AAA GmbH - Honorar Vortragstätigkeit Fa. NVision Imaging Technologies GmbH Ulm - Mitglied Scientific Advisory Board - Ärztlicher Direktor Klinik für Nuklearmedizin, Universitätsklinikum Ulm - Präsident Südwestdeutsche Gesellschaft für Nuklearmedizin SWDGN - Forschungskooperation PET/MRT mit Siemens Healthcare GmbH Erlangen, (Thieme. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.